Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP)
NCT02788318 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2
Last updated 2019-04-03
Summary
The mortality rate is increased in patients with epilepsy, and especially among patients with drug-resistant epilepsy. This increased mortality is mainly related to the risk of SUDEP whose incidence is between 3.5 and 9 per 1,000 for patients with drug-resistant epilepsy. The term SUDEP refers to a sudden death occurring in a patient with epilepsy in whom anamnestic and post-mortem evidence does not identify a particular cause. Experimental and clinical data strongly suggest that most of SUDEP result from a postictal respiratory dysfunction progressing to terminal apnea. Due to the major role of serotonin in regulating breathing rhythms and data in animal models of epilepsy, it is envisaged that an alteration of serotonergic systems of the brainstem and limbic regions may play a central role in the occurrence of SUDEP. The objective of this work is to look for abnormalities of the serotonergic transmission within regulatory regions of respiratory and autonomic functions in brain samples prospectively collected in patients died from SUDEP.
Conditions
- Sudden Unexpected Death in Epilepsy (SUDEP)
Interventions
- OTHER
-
Brain samples
Collected in patients died
- OTHER
-
Skin samples
Collected in patients died
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-01-31
- Primary Completion
- 2019-01-31
- Completion
- 2019-01-31
Countries
- France
Study Locations
More Related Trials
-
Assessment of Suicidality in Epilepsy - Rating Tools
NCT01085461 ·Status: COMPLETED
-
Epidemiology of Suspected Epileptic Seizures
NCT04147663 ·Status: UNKNOWN
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
NCT02929667 ·Status: COMPLETED ·Phase: PHASE2
-
Study for the Diagnosis and Treatment of Drug-resistant Focal Epilepsies
NCT06794606 ·Status: RECRUITING
-
Cardiac Arrhythmias in Dravet Syndrome
NCT02415686 ·Status: COMPLETED
-
Antiepileptic Drugs and Vascular Risk Markers
NCT00774306 ·Status: TERMINATED ·Phase: NA
-
Study of Cannabidiol for Drug-Resistant Epilepsies
NCT03014440 ·Status: NO_LONGER_AVAILABLE
-
Cardiovascular Risk Reduction in Epilepsy
NCT05704439 ·Status: WITHDRAWN ·Phase: NA
-
BOTOX Effects on Seizure Severity and Susceptibility
NCT05605756 ·Status: TERMINATED ·Phase: PHASE4
-
Stiripentol in Dravet Syndrome
NCT01533506 ·Status: NO_LONGER_AVAILABLE
-
Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
NCT05772429 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial Epilepsy
NCT01501383 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy of Fluoxetine in Reducing Ictal Hypoventilation in Patients With Partial Epilepsy
NCT00986310 ·Status: COMPLETED ·Phase: NA
-
Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy
NCT02220114 ·Status: COMPLETED ·Phase: NA
-
Novel Network Analysis of Intracranial Stereoelectroencephalography
NCT03916848 ·Status: UNKNOWN ·Phase: NA
-
Pharmacodynamics of Nasal and Buccal Midazolam Using EEG
NCT01316445 ·Status: TERMINATED ·Phase: PHASE1
-
STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy
NCT00228371 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Epilepsy-related Brain Tumors Register
NCT03876093 ·Status: WITHDRAWN
-
Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
NCT02052739 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Interest of a Specific Care Pathway for the Management of Catamenial Epilepsy
NCT05898152 ·Status: UNKNOWN
-
Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
NCT03373383 ·Status: COMPLETED ·Phase: PHASE2
-
Multicentre Real-life Follow-up Study of Rare Epileptic Syndromes in Children and Adolescents
NCT05126914 ·Status: RECRUITING
-
Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
NCT00228969 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
NCT06377930 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset Seizures
NCT01227902 ·Status: COMPLETED ·Phase: PHASE3